|
PSCI-20-100 |
Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence |
|
PSCI-20-117 |
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA?) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma |
|
PSCI-20-118 |
NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial |
|
PSCI-20-129 |
Evaluation of Biomarkers in Bladder Cancer Patients in the Neoadjuvant Setting |
|
PSCI-20-137 |
Specimen Banking with Clinical and Genomic Data Registry with the Establishment of Tumor Models for Pediatric Cancers. |
|
PSCI-20-141 |
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*) |
|
PSCI-21-002 |
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma |
|
PSCI-21-008 |
Pilot study to evaluate if contrast-enhanced ultrasound (CEUS) can predict treatment response in triple negative breast cancer (TNBC) patients receiving combined chemotherapy and Immune Checkpoint Inhibitors (ICI). |
|
PSCI-21-019 |
Effectiveness of smoking cessation resources available to patients of the Penn State Cancer Institute (PSCI) |
|
PSCI-21-026 |
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA) |
